Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Veru Inc. (VERU)

Pharmaceutical Preparations

https://www.verupharma.com

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

2916 N. MIAMI AVENUE, SUITE 1000
MIAMI, FL

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/01/1990

Market Cap

121,981,787

Shares Outstanding

137,620,000

Weighted SO

146,291,030

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

MCRB --.--%

PLX --.--%

LXRX --.--%

IOVA --.--%

IMGN --.--%

TSVT --.--%

ICPT --.--%

PBYI --.--%

SRPT --.--%

Beta

-0.4270

Last Div

0.0000

Range

0.36-1.92

Chg

-0.0067

Avg Vol

1615237

Mkt Cap

121981787

Exch

NASDAQ

Country

US

Phone

305 509 6897

DCF Diff

3.5088

DCF

-1.7188

Div Yield

0.0000

P/S

8.6562

EV Multiple

-2.5739

P/FV

3.2424

Div Yield %

0.0000

P/E

-2.2998

PEG

0.4830

Payout

0.0000

Current Ratio

3.6230

Quick Ratio

3.1576

Cash Ratio

2.7449

DSO

42.5317

DIO

192.2343

Op Cycle

234.7660

DPO

117.4016

CCC

117.3645

Gross Margin

0.3341

Op Margin

-3.7830

Pretax Margin

-3.7049

Net Margin

-3.7638

Eff Tax Rate

-0.0159

ROA

-0.8206

ROE

-1.3938

ROCE

-0.9870

NI/EBT

1.0159

EBT/EBIT

0.9794

EBIT/Rev

-3.7830

Debt Ratio

0.1640

D/E

0.2818

LT Debt/Cap

0.1857

Total Debt/Cap

0.2199

Int Coverage

-136.6445

CF/Debt

-2.5286

Equity Multi

1.7180

Rec Turnover

8.5818

Pay Turnover

3.1090

Inv Turnover

1.8987

FA Turnover

2.6852

Asset Turnover

0.2180

OCF/Share

-0.1831

FCF/Share

-0.1852

Cash/Share

0.1991

OCF/Sales

-1.9024

FCF/OCF

1.0115

CF Coverage

-2.5286

ST Coverage

-13.2377

CapEx Coverage

-86.9960

Div&CapEx Cov

-86.9960

P/BV

3.2424

P/B

3.2424

P/S

8.6562

P/E

-2.2998

P/FCF

-4.4984

P/OCF

-4.5501

P/CF

-4.5501

PEG

0.4830

P/S

8.6562

EV Multiple

-2.5739

P/FV

3.2424

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 08, 08:30 Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss GlobeNewswire Inc. Dec 19, 08:30 Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
0.07 04/28/2014 03/24/2014 04/30/2014 05/07/2014
0.07 01/27/2014 12/16/2013 01/29/2014 02/05/2014
0.07 10/28/2013 10/04/2013 10/30/2013 11/06/2013
0.07 07/29/2013 07/15/2013 07/31/2013 08/07/2013
0.07 04/29/2013 03/27/2013 05/01/2013 05/08/2013
0.06 01/28/2013 01/03/2013 01/30/2013 02/06/2013
0.06 10/31/2012 10/05/2012 10/31/2012 11/07/2012
0.06 10/29/2012 11/30/-0001 11/30/-0001 11/30/-0001
0.06 07/30/2012 07/13/2012 08/01/2012 08/08/2012
0.06 04/30/2012 03/27/2012 05/02/2012 05/09/2012
0.05 01/30/2012 01/05/2012 02/01/2012 02/09/2012
0.05 10/31/2011 10/07/2011 11/02/2011 11/09/2011
0.05 07/29/2011 07/14/2011 08/02/2011 08/09/2011
0.05 04/29/2011 04/13/2011 05/03/2011 05/10/2011
0.05 01/27/2011 01/14/2011 01/31/2011 02/07/2011
0.05 11/01/2010 10/08/2010 11/03/2010 11/10/2010
0.05 08/02/2010 07/22/2010 08/04/2010 08/11/2010
0.05 04/21/2010 04/12/2010 04/23/2010 05/12/2010
0.05 01/27/2010 01/19/2010 01/29/2010 02/16/2010